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ABSTRACT
Objectives: This study compared the profile of
intentional drug overdoses (IDOs) presenting to
emergency departments in Ireland and in the Western
Trust Area of Northern Ireland between 2007 and
2012. Specifically the study aimed to compare
characteristics of the patients involved, to explore the
factors associated with repeated IDO and to report the
prescription rates of common drug types in the
population.
Methods: We utilised data from two comparable
registries which monitor the incidence of hospital-
treated self-harm, recording data from deliberate self-
harm presentations involving an IDO to all hospital
emergency departments for the period 1 January 2007
to 31 December 2012.
Results: Between 2007 and 2012 the registries
recorded 56 494 self-harm presentations involving an
IDO. The study showed that hospital-treated IDO was
almost twice as common in Northern Ireland than in
Ireland (278 vs 156/100 000, respectively).
Conclusions: Despite the overall difference in the
rates of IDO, the profile of such presentations was
remarkably similar in both countries. Minor
tranquillisers were the drugs most commonly involved
in IDOs. National campaigns are required to address
the availability and misuse of minor tranquillisers, both
prescribed and non-prescribed.
INTRODUCTION
Intentional drug overdose (IDO) is the most
common form of hospital-treated suicidal
behaviour,1 2 accounting for 65–85%2 3 of self-
harm presentations to emergency departments
and 1–2% of all hospital admissions.4–6 The
most common type of drug taken in IDOs is
psychotropic medication, in particular benzo-
diazepines/minor tranquillisers.7–11 Analgesics
such as paracetamol are also common, particu-
larly in England.12 It has been shown that the
vast majority of IDO patients take their own
medication whether prescribed or available
over the counter.11 13 14 The prevalence of
drugs taken in IDOs has been shown to reﬂect
their prescription and availability in the
population.6 15
Studies of the drugs taken in IDO have led
to effective changes in policy and legislation.
In Ireland and the UK, paracetamol pack
sizes were reduced and co-proxamol/distal-
gesic was withdrawn from the market, mea-
sures which were associated with reduced
suicidal behaviour.16 17
There have been few comparative studies
of countries in relation to the incidence of
IDOs, the proﬁle of patients, the types of
drugs involved and the availability of these
drugs in the populations. We aimed to
examine these differences for the Western
Area of Northern Ireland and the Republic
Strengths and limitations of this study
▪ Intentional drug overdose (IDO) is the most
common form of hospital-treated suicidal behav-
iour and the most common type of drug involved
is psychotropic medication, in particular benzo-
diazepines/minor tranquillisers. The prevalence
of drugs taken in IDOs has been shown to reflect
their prescription and availability in the
population.
▪ There have been few comparative studies of
countries in relation to the incidence of IDOs, the
profile of patients, the types of drugs involved
and the availability of these drugs in the
populations.
▪ This study has, for the first time, compared the
profile of hospital-treated IDO in two countries
(Ireland and Northern Ireland).
▪ While the profile of these presentations is similar
across both samples, a higher incidence of IDOs
is being observed in Northern Ireland.
▪ This study further raises the question that is
there a higher prevalence of mental disorders in
Northern Ireland, or is this a difference due to
increased help-seeking behaviour. Further
research is required to establish a clearer picture
of the circumstances and psychological back-
ground of IDO presentations in both countries.
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of Ireland utilising two comparable registries which
monitor the incidence of hospital-treated self-harm. We
compare characteristics of the patients involved, explore
the factors associated with repeated IDO and report the
prescription rates of common drug types in the
population.
METHODS
National registry of deliberate self-harm Ireland
This Registry was established in 2002 and its primary
purpose is to determine and monitor the incidence and
patterns of hospital-treated deliberate self-harm. Since
2006, all emergency departments in Ireland (population
4 585 500)18 have contributed data to the Registry. This
study involved data from deliberate self-harm presentations
involving an IDO to all hospital emergency departments
for the period 1 January 2007 to 31 December 2012.
Northern Ireland Registry of Deliberate Self-Harm
The Northern Ireland Registry of Deliberate Self-Harm
is part of the Northern Ireland Suicide Prevention
Strategy ‘Protect Life—A Shared Vision’ and has been
collecting data since 2007, using a methodology adapted
from that of the National Registry of Deliberate
Self-Harm Ireland. This study involved data from deliber-
ate self-harm presentations involving an IDO to the
three emergency departments in Northern Ireland’s
Western Trust Area (population 298 303)19 for the
period 1 January 2007 to 31 December 2012. The
Western Area provides representation of all settlement
bands in Northern Ireland20 and has a similar incidence
and pattern of hospital-treated self-harm as Northern
Ireland as a whole.21
Definition of self-harm
Both registries involved in this study use the following as
their deﬁnition of deliberate self-harm: ‘an act with non-
fatal outcome in which an individual deliberately initi-
ates a non-habitual behaviour, that without intervention
from others will cause self-harm, or deliberately ingests a
substance in excess of the prescribed or generally recog-
nised therapeutic dosage, and which is aimed at realis-
ing changes that the person desires via the actual or
expected physical consequences’.22 This deﬁnition was
derived for the Euro/WHO multicentre study and it is
consistent with that used in the multicentre monitoring
project in England.1 The deﬁnition includes acts involv-
ing varying levels of suicidal intent and various under-
lying motives such as loss of control, cry for help or
self-punishment.
Data collection
Data collection is carried out by data registration ofﬁcers
who work speciﬁcally for the registries. The data registra-
tion ofﬁcers receive standard training in data collection
methods and attend regular review meetings. Searches
for cases of deliberate self-harm involve a combination
of manually checking consecutive presentations to the
emergency departments, selecting potential cases on the
basis of keyword searches and triage coding by hospital
staff. Flexibility in case ﬁnding is required because of dif-
ferences between hospital systems of recording emer-
gency department presentations. However, the data
registration ofﬁcers operate independent of the emer-
gency department staff, with the priority of ensuring
standardised case ascertainment.
Inclusion and exclusion criteria
IDO cases were included in this study where it was clear
that the self-harm was deliberately inﬂicted. The follow-
ing examples are not considered to be self-harm cases:
unintentional overdoses such as an individual taking
excessive medication in the case of illness (without
intention to harm oneself) or an individual who pre-
sents to hospital following an overdose of street drugs
taken for recreational purposes. In addition, a distinc-
tion between IDO and deliberate self-poisoning is made.
IDO encompasses methods of self-harm with ICD-10
code of X60-64 (overdose of drugs and medicaments),
and cases with any of these codes were included in the
analysis for this paper. In this study, medicinal and street
drug overdoses are covered by the term IDO. Cases
involving other poisons (eg, chemicals) and only
alcohol, regardless of intent, are not included in this
sample.
Data items
Both registries have a core data set including the follow-
ing variables: gender, date of birth, date and hour of
attendance at hospital, method(s) of self-harm and
recommended next care. In addition, patient initials (in
an encrypted format) and area of residence, coded to
administrative area, are recorded. For IDO cases, the fol-
lowing data are also recorded: drug taken and the total
number of tablets taken (by drug name). Drugs were
classiﬁed into groups of drug type by consulting the
WHO’s anatomical-therapeutic-chemical (ATC) system
of drug classiﬁcation, the British National Formulatory
(BNF) and the Irish Monthly Index of Medical
Specialities (MIMS).
Availability of psychotropic drugs
Data on sales of psychotropic drugs to pharmacies in
Ireland and Northern Ireland for the study period 2007–
2012 were supplied by IMS Health Inc (http://www.
imshealth.com). The number of tablets sold to pharma-
cies per 1000 population in Ireland and Northern
Ireland was calculated to give an indication of the avail-
ability of psychotropic drugs in the communities.
Data analysis
For the years 2007–2012, the annual incidence rate of
IDOs per 100 000 population was calculated for the
total, male and female populations (and for age–sex sub-
groups) based on the number of persons who presented
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to hospital in the catchment area. We calculated 95%
CIs for the rates using the Normal Approximation of
Poisson Distribution. These intervals are displayed by
error bars in the relevant chart.
Repeat acts are deﬁned as presentation to a hospital
emergency department in the catchment area due to an
act of self-harm within 12 months of leaving hospital fol-
lowing treatment in an emergency department for an
index IDO act, during the years 2007–2011.
A multivariate logistic regression model was developed
to identify factors related to the index IDO that were
independently associated with repeated self-harm within
12 months. ORs and their 95% CIs are reported with
the associated level of signiﬁcance.
RESULTS
Characteristics of hospital-treated IDO
Between 2007 and 2012, there were 56 494 IDO presen-
tations to emergency departments, 50 394 (89%) in
Ireland and 6100 (11%) in the Western Area of
Northern Ireland (henceforth referred to as Northern
Ireland). The characteristics of IDO presentations were
very similar in both countries (table 1). In Ireland and
Northern Ireland, almost 60% of IDO presentations to
hospitals were made by women and by persons under
35 years of age. The mean number of tablets taken in an
IDO act was 30 and approximately one in six made a
self-harm presentation to hospital within 12 months of
their index IDO act.
The involvement of alcohol in IDO presentations was
signiﬁcantly higher in Northern Ireland (60% vs 43%;
χ2=586.74, df=1, p<0.001). The countries also differed in
relation to recommended aftercare (χ2=1922.87, df=4,
p<0.001). In Northern Ireland, patients were more often
admitted to a general ward following an IDO presenta-
tion and less likely to leave before aftercare was
recommended.
Incidence of IDOs
Overall, the rate of IDO presentations in Northern
Ireland (278 (95% CI 271 to 286) per 100 000) was 78%
higher than what it was in Ireland (156 (95% CI 155 to
158) per 100 000). Despite this difference, the pattern
in the incidence rate when examined by age was similar
for both countries (ﬁgure 1). The peak rate was
observed among 20–24-year-olds in Ireland (328/
100 000) and Northern Ireland (578/100 000). The inci-
dence rate decreased with increasing age, with a slight
secondary peak seen among those aged 35–49 years.
The IDO rate was very low, and similar in both countries,
among over 60-year-olds.
Drugs involved in IDOs
Figure 2 illustrates the categories of drugs which were
used in IDOs, for both countries. A minor tranquilliser
was involved in 40% of IDOs, and their use was higher
in Ireland than in Northern Ireland (42% vs 27%,
χ2=489.85, df=1, p<0.001). Drugs including only para-
cetamol were involved in 21% of IDO presentations in
both countries but paracetamol-compound drugs were
more common in Northern Ireland (13% vs 9%,
χ2=95.86, df=1, p<0.001). The only other common drug
type involved in IDOs was antidepressants (including
selective serotonin re-uptake inhibitors (SSRIs), tricyclic
antidepressants (TCADs) and mood-stabilisers), present
in 22% of acts. SSRIs were the most common type of
antidepressants (used in 13% of acts). ‘Other drugs’
were taken in 25% of cases.
Although the involvement of opiate-based drugs was
low overall, they were more common in IDO presenta-
tions in Northern Ireland (opiate-compound drugs 13%
vs 8%; χ2=149.38, df=1, p<0.001; opiate-only drugs 7% vs
5%; χ2=47.09, df=1, p<0.001). While relatively rare, street
drugs were involved more often in IDOs in Ireland (6%
vs 2%; χ2=175.06, df=1, p<0.001).
The use of minor tranquillisers increased with age,
especially in Ireland (ﬁgure 3). The prevalence of anti-
depressant drugs was similar in IDOs by persons aged
over 25 years. Paracetamol-containing drugs were most
common in IDOs by young people.
Repeated self-harm following IDO
The rate of repetition of self-harm after an index IDO
act was similar in Ireland and Northern Ireland, with
16% of individuals representing to an emergency
department within 12 months (table 2). The risk of
repetition was increased among those aged less than
Table 1 Demographics of intentional drug overdose
sample from Ireland and Northern Ireland
Characteristic
Ireland
n=50 394
(%)
Northern
Ireland
n=6100
(%)
Gender
Male 41.5 43.4
Female 58.5 56.6
Age (years)
<15 1.8 1.5
15–24 28.5 26.7
25–34 24.1 22.6
35–44 22.0 25.1
45–54 15.0 17.6
55+ 8.3 6.5
Number of tablets (mean) 30 29
Alcohol involvement 43.2 59.5
Rate of repetition 15.9 17.9
Aftercare
General ward 36.3 63.6
Psychiatric ward 8.0 4.6
Patient refused admission 1.1 2.8
Patient left without
recommendation
12.9 5.9
Not admitted 41.7 23.1
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55 years, when the initial IDO also involved self-cutting
and alcohol and when 40–69 tablets were taken in the
act. Patients admitted to a psychiatric ward after the
index IDO were more likely to repeat. Psychotropic
drugs (minor and major tranquillisers, SSRIs, antiepilep-
tics and other antidepressants) were associated with
higher rates of repetition. After adjustment for the
range of factors examined, there was still an increased
rate of repetition following IDO presentations in
Northern Ireland.
Availability of psychotropic drugs
Antidepressants (including mood stabilisers) were by far
the most available type of psychotropic drugs in pharma-
cies. There was greater availability of psychotropic drugs
in Northern Ireland than in Ireland (table 3). This was
most pronounced for antidepressants and mood stabili-
sers and for tranquillisers, which were almost twice as
available in Northern Ireland.
DISCUSSION
In this study, we compared the proﬁle of IDO presenta-
tions to emergency departments in Ireland and the
Western Area of Northern Ireland. We found that the
incidence rate of IDO presentations to hospital and the
availability of antidepressants and tranquillisers were
twice as high in Northern Ireland. Despite this, the
proﬁle of IDO presentations in terms of gender, age, the
type of drug and the number of tablets taken were
similar in both countries.
In both countries, minor tranquillisers were the drugs
most commonly involved in IDOs. The ﬁndings of this
study in relation to the overall involvement of minor
tranquillisers differ from UK studies, where benzodiaze-
pines were reported to have been involved in 14.8% of
self-poisoning episodes,23 and are considerably lower
than that reported by a Spanish study of deliberate over-
dose where benzodiazepines were involved in 65% of
cases.7 Paracetamol is the most commonly used drug in
IDOs in England.1 There are similar regulations in rela-
tion to pack sizes of paracetamol in England and
Northern Ireland, but the proportion of IDOs in the
latter is more similar to that in Ireland, where different
pack sizes are available. This may be due to the overall
sales of paracetamol, which is worthy of further investiga-
tion. Variations in the use of medications by age were
also observed in this study, with paracetamol
Figure 1 Incidence of
hospital-treated intentional drug
overdose (IDO) by 5-year age–
sex group.
Figure 2 Drugs used intentional
drug overdose (IDO).
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involvement in IDOs most common in younger age
groups, while minor tranquillisers and antidepressants
were more common in older adults. These ﬁndings are
consistent with those reported by Townsend et al12 and
Hendrix et al.9
Alcohol involvement in IDO presentations was higher
than that reported by other studies9 and higher in
Northern Ireland than in Ireland. However, the rate of
alcohol involvement in Northern Ireland was very
similar to that reported in the UK, suggesting a cultural
pattern of alcohol misuse.1 3 Overall, the patterns of
alcohol involvement by age and gender are consistent
with those observed by Hawton et al.1
The rate of repetition following an index IDO episode
was higher in Northern Ireland than in Ireland.
However, both rates were similar to that reported by a
previous systematic review24 and within the range of 14–
23% of recent UK studies based on 1-year-person-based
rates of repetition.3 25 26 Signiﬁcant variation in repeti-
tion was observed across drug types. Despite having low
toxicity,7 this study found that the rates of repetition
involving minor tranquillisers in particular are relatively
high. This is in line with Cooper et al’s3 Manchester
Self-Harm Rule which indicates that cases of self-harm
where benzodiazepines are not involved are at a lower
risk for repetition.
The drugs taken in IDOs are generally thought to
reﬂect ease of access or prescription patterns in that
country.5 27 The results of this study indicated that the
incidence of IDO presentations to hospital and the avail-
ability of psychotropic medication are signiﬁcantly
higher in Northern Ireland than in Ireland. The ﬁnd-
ings reﬂect those reported by the Irish National
Advisory Committee on Drugs, where a lifetime preva-
lence of tranquilliser use and antidepressant use was
14% and 10% in Ireland and 21% and 22% in Northern
Ireland, respectively.28 These ﬁndings indicate a higher
prevalence of psychiatric disorders and mental illness in
Northern Ireland. This is further supported by studies
which have found a high prevalence of DSM-IV disor-
ders in the Northern Ireland population29 and of post-
traumatic stress disorder (PTSD).30 DSM-IV disorders
are highly prevalent in the Northern Ireland population
and are on the high end of the scale when compared
with international ﬁgures.29 31 It is argued that the high
incidence of PTSD in the Northern Ireland population
indicates that the effects of chronic trauma exposure
continue to impact negatively on mental health in
Northern Ireland.30 However, rather than simply point-
ing to a higher prevalence of psychiatric disorders in
Northern Ireland, the higher IDO rates found in our
study could reﬂect better access to health services. It has
been indicated that 50% patients with mood disorders
sought treatment in the ﬁrst year following onset and
suggested that treatment adequacy among individuals
seeking treatment in Northern Ireland was higher than
in the USA or Europe.31 The delays between initial
onset of disorders and seeking treatment (particularly
in substance disorders) however reﬂect a lack of aware-
ness31 and this, along with the high percentage of
alcohol involved in IDOs suggests that more targeted
interventions are needed to address underlying mental
health disorders in the general population.
Conversely, both countries in this study have different
healthcare systems. As part of the UK, Northern Ireland
residents have free healthcare at the point of delivery
under the National Health Service. In addition to this,
all prescriptions dispensed in Northern Ireland are free
of charge. In Ireland, however the Health Service
Executive (HSE) operates a medical card scheme, where
free access to services is means-tested. Without a medical
card, there is a fee for each hospital emergency depart-
ment visit. For prescription sales a small charge applies
to each dispensed prescription for those with medical
cards, however for those without this card the full value
of the prescription is charged. This difference in emer-
gency department visits may account for the larger rate
of self-harm and IDO presentations to emergency
departments in Northern Ireland, given that each visit is
without charge. In addition, prescribing rates and the
availing of prescription medication by residents of
Northern Ireland may be partially explained by the cost
of such medication. Further work is required to investi-
gate how charges associated with prescription of medica-
tion and presentation to hospital have an impact on
incidence rates.
It has been previously argued that the involvement of
certain prescription medications in IDOs is related to
Figure 3 Drugs taken by age for Ireland (left) and Northern Ireland (right). Chart adapted from Hawton et al.1
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their prescription, despite the established efﬁcacy of psy-
chotropic drugs in treating psychiatric conditions.
Previous studies have highlighted the importance of con-
sidering risk of IDO among patients prescribed minor
tranquillisers.7 11 13 A previous Irish study found that
having a prescription for a minor tranquilliser increased
the risk of using a psychotropic drug in an IDO, inde-
pendent of any other studied factor. A high proportion
of this sample had been in contact with the psychiatric
services at the time of their overdose, indicating an
underlying need for monitoring prescribed medication,
particularly among older people.13 In addition, the
National Institute for Health and Care Excellence
(NICE) guidelines state that the prescription of psycho-
tropic medication should be considered a public health
issue.32
Table 2 Factors associated with repeated self-harm within 12 months of an intentional drug overdose presentation
Factor
Repetition
N (%) Adjusted OR 95% CI
Gender
Male 2454 (17.3) 1.08* 1.01 to 1.16
Female 3014 (15.3) 1.00 Ref
Age group (years)
<15 119 (16.7) 1.78*** 1.35 to 2.35
15–24 1595 (14.9) 1.44*** 1.23 to 1.68
25–34 1332 (16.5) 1.38*** 1.18 to 1.62
35–44 1296 (18.5) 1.59*** 1.36 to 1.86
45–54 785 (16.8) 1.40*** 1.18 to 1.65
55+ 341 (12.5) 1.00 Ref
Alcohol 2555 (16.9) 1.15*** 1.07 to 1.23
Self-cutting 502 (26.3) 1.94*** 1.69 to 2.22
Tablets taken
<10 586 (15.4) 1.00 Ref
10–19 1019 (14.5) 1.00 0.89 to 1.12
20–29 810 (15.1) 1.04 0.92 to 1.17
30–39 503 (16.6) 1.13 0.99 to 1.29
40–49 383 (18.7) 1.30*** 1.12 to 1.50
50–59 209 (17.9) 1.20* 1.00 to 1.44
60–69 161 (18.5) 1.26* 1.03 to 1.54
70–79 72 (14.5) 0.88* 0.67 to 1.16
80+ 240 (17.3) 1.12 0.94 to 1.33
Admission
General ward 2130 (15.7) 1.00 Ref
Psychiatric ward 587 (25.1) 1.75*** 1.55 to 1.99
Patient refused admission 70 (17.8) 1.12 0.82 to 1.52
Patient left without recommendation 678 (17.9) 1.16* 1.03 to 1.31
Not admitted 2003 (14.5%) 0.93 0.86 to 1.01
Drug-type
Salicylate 98 (12.2) 0.80 0.63 to 1.03
Salicylate compound 77 (12.1) 0.92 0.71 to 1.19
Paracetamol 983 (13.4) 0.98 0.89 to 1.07
Paracetamol compound 450 (12.9) 0.91 0.68 to 1.23
Opiate 284 (16.2) 1.10 0.94 to 1.29
Opiate compound 407 (13.2) 0.97 0.70 to 1.33
NSAID 685 (13.6) 0.96 0.86 to 1.06
Minor tranquilliser 2548 (19.5) 1.55*** 1.44 to 1.68
Major tranquilliser 551 (22.8) 1.56*** 1.38 to 1.76
SSRI 802 (18.4) 1.16** 1.05 to 1.28
TCAD 75 (14.5) 0.98 0.73 to 1.31
Other antidepressants 469 (19.1) 1.26*** 1.11 to 1.42
Antiepileptic/barbiturate 291 (22.6) 1.54*** 1.31 to 1.81
Other drugs 1341 (15.6) 1.06 0.97 to 1.16
Street drugs 374 (18.5) 1.12 0.94 to 1.34
Country
Ireland 4868 (15.9) 1.00 Ref
Northern Ireland 600 (17.9) 1.24*** 1.10 to 1.39
*p<0.05; **p<0.01; ***p<0.001.
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Strengths and limitations
This study compared ﬁndings from two highly compar-
able registry systems which utilise the same deﬁnition of
self-harm and drug type, and similar operating proce-
dures. The large sample size allowed for the calculation
of precise rates of IDO presentations in Ireland and the
Western Area of Northern Ireland.
There are however a number of limitations due to the
limited range of data recorded by the registries. We
could not explore the management and treatment of
presentations to emergency departments following an
IDO, whether an individual’s own prescribed medication
was used in the act, or if the patient had a psychiatric
diagnosis. The study period was also too short to observe
trends in the rate of IDO presenting to emergency
departments in Ireland and Northern Ireland, but
further work will address this research question.
Northern Ireland self-harm data for the study period
were only available for the Western Area. Future work
would include self-harm data from other trust regions of
Northern Ireland. A further limitation is that the pre-
scription rates are produced for Northern Ireland, and
not just for the study area in this study.
Conclusion
The results of this study have, for the ﬁrst time, com-
pared the proﬁle of hospital-treated IDO in samples
from two countries. Remarkably, the proﬁle of these pre-
sentations is similar across both samples, particularly in
relation to the type of drug used in IDOs. Despite this
similarity, the incidence of IDOs in the Western Area of
Northern Ireland was higher than in Northern Ireland.
A ﬁrst look at the rates of prescription of medication in
both countries further raises the question of whether
there is a higher prevalence of mental disorders in
Northern Ireland, or this difference is due to increased
help-seeking behaviour in Northern Ireland. Further
research is required to establish a clearer picture of the
circumstances and psychological background of IDO
presentations in both countries.
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